-
Description
MenQuadfi Meningococcal 0.5ml Vial
Product Description:
MenQuadfi is a quadrivalent meningococcal conjugate vaccine designed to provide active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Each 0.5ml vial contains a sterile suspension that is ready for intramuscular injection, providing a convenient and efficient solution for immunization programs.
Technical Specifications:
- Dosage Form: 0.5ml vial for intramuscular injection
- Conjugate Vaccine: Targets serogroups A, C, W, and Y
- Preservative-Free: Ensures safety and minimizes adverse reactions
- Storage: Refrigerated between 2°C and 8°C (35°F and 46°F)
- Shelf Life: Extended stability for efficient stock management
Common Applications and User Groups:
MenQuadfi is commonly administered to:
- Adolescents and young adults, particularly those living in close quarters such as college dormitories or military barracks
- Travelers to regions where meningococcal disease is endemic or epidemic
- Individuals with compromised immune systems or asplenia
- Healthcare professionals recommend routine vaccination for individuals aged 11 through 18 years, with a booster dose for continued protection
Supplier Overview:
Sanofi Aventis, a global leader in healthcare, is renowned for its commitment to innovation and patient care. With a rich history in vaccine development, Sanofi Aventis has established itself as an authority in the field of immunization. Their dedication to quality, safety, and efficacy positions them at the forefront of combating infectious diseases worldwide. The introduction of CC MenQuadfi Meningococcal 0.5ml Vial further exemplifies their role in advancing public health and protecting communities against the threat of meningococcal disease.
